Condition
Bone and Soft Tissue Tumors
Total Trials
5
Recruiting
4
Active
4
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Recruiting4
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06939855Phase 2RecruitingPrimary
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
NCT06599957RecruitingPrimary
Innovative Drug Delivery Nanophotonic Platform for Implementation of Sarcoma Therapy
NCT07112989RecruitingPrimary
Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors
NCT05468970RecruitingPrimary
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
NCT03159585Phase 1Completed
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
Showing all 5 trials